The research, funded by the National Institutes of Health, was published Friday as European and U.S. regulators look into anecdotal reports that people taking semaglutide, had thoughts of self-harm.
People taking the popular diabetes and obesity drugs Ozempic and
In December, the EMA’s drug watchdog group said it would seek more data from drugmaker Novo Nordisk about the reports.
The U.S. Food and Drug Administration also is investigating unconfirmed reports of suicidal thoughts or actions in people taking the GLP-1 drugs.
Millions of people in the U.S. are taking semaglutide, which has soared in popularity since Wegovy was approved to treat obesity in June 2021.
A spokesperson for Novo Nordisk said the new study reflects the company’s data collected from large clinical trials and since the drug has been on the market — all of which showed no “causal association” between semaglutide and thoughts of suicide or self-harm.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Never miss a beat: Get our daily stories straight to your inbox with theGrio’s newsletter.
The post People on Wegovy, Ozempic have lower risk of suicidal thoughts, study finds appeared first on TheGrio.
New Comments